BFM
JSPR icon

Boothbay Fund Management’s Jasper Therapeutics JSPR Stock Holding History

Boothbay Fund Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-582,751
Closed -$511K – 2446
2026
Q1 		$511K Sell
582,751
-211,203
-27% -$293K 0.01% 1340
2025
Q4 		$1.45M Buy
793,954
+351,312
+79% +$705K 0.02% 675
2025
Q3 		$1.05M Buy
+442,642
New +$1.34M 0.02% 814
2025
Q1 		– Sell
-13,853
Closed -$296K – 1589
2024
Q4 		$296K Buy
13,853
+1,617
+13% +$33.7K 0.01% 1072
2024
Q3 		$230K Sell
12,236
-11,088
-48% -$221K 0.01% 1356
2024
Q2 		$529K Hold
23,324
– – 0.01% 975
2024
Q1 		$685K Buy
+23,324
New +$414K 0.01% 891
2023
Q4 		– Sell
-23,316
Closed -$163K – 1823
2023
Q3 		$163K Hold
23,316
– – ﹤0.01% 1471
2023
Q2 		$319K Sell
23,316
-25
-0.1% -$371 0.01% 1269
2023
Q1 		$422K Buy
+23,341
New +$431K 0.01% 1323
2020
Q3 		– Sell
-6,060
Closed -$614K – 1131
2020
Q2 		$614K Buy
+6,060
New +$592K 0.04% 525

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Boothbay Fund Management's JSPR Position: Q2 2026 in Review

Boothbay Fund Management sold out of Jasper Therapeutics (JSPR) in Q2 2026, closing a stake of 582,751 shares — an estimated $511K sold.

Boothbay Fund Management first reported a position in JSPR in Q2 2020 and held it in 11 quarters. The position peaked at $1.45M in Q4 2025. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • Boothbay Fund Management reported no remaining Jasper Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 582,751 Jasper Therapeutics shares in Q2 2026, an estimated $511K.
  • Boothbay Fund Management first reported a position in Jasper Therapeutics in Q2 2020 and held it in 11 quarters.
  • Boothbay Fund Management's Jasper Therapeutics position peaked at $1.45M in Q4 2025.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.